Market Newsdesk

HAMILTON, Bermuda, Feb. 5, 2021 /PRNewswire/ — Third Point Reinsurance Ltd. (NYSE: TPRE) (“Third Point Re”), a specialty reinsurer, and Sirius International Insurance Group, Ltd. (Nasdaq: SG) (“Sirius Group”), a global multi-line insurer and reinsurer, today announced that they have set the deadline for shareholders of Sirius Group to make an election with respect to the form of consideration they wish to receive pursuant to the Agreement and Plan of Merger, dated as of August 6, 2020, by and among Sirius Group, Third Point Re and Yoga Merger Sub Limited (the “Merger Agreement”).  The election deadline is 5:00 p.m., New York City time (6:00 p.m., Bermuda time), on February 11, 2021.  Third Point Re and Sirius Group currently expect to consummate the transactions contemplated by the Merger Agreement on or about February 26, 2021, subject to the satisfaction of all closing conditions.  The election deadline will be similarly extended in the event the anticipated closing date is delayed to a subsequent date, in which case Third Point Re and Sirius Group will promptly announce any such delay and, when determined, the rescheduled election deadline.

Registered Sirius Group shareholders are reminded that if they wish to make an election, they must complete, sign and return a Form of Election and Letter of Transmittal to Computershare Trust Company, N.A., as exchange agent, by the election deadline.  Shareholders holding shares through a broker, bank or other nominee should carefully follow the instructions provided by such broker, bank or other nominee to make an election.  Such shareholders may be subject to an earlier deadline from their brokers, banks or nominees for making an election.  Holders of Sirius Group shares who fail to make a timely election or who make no election will be deemed to have agreed to make a Share & CVR election in respect of the Sirius Group shares they hold.  Shareholders with questions should contact Georgeson LLC, in its capacity as Third Point Re’s information agent, toll free at (866) 828-4304.

About Third Point Re
Third Point Reinsurance Ltd. (Third Point Re) is a Bermuda headquartered holding company listed on the New York Stock Exchange (TPRE).  The company underwrites specialty, property and casualty business through its wholly-owned subsidiaries, Third Point Reinsurance Company Ltd. and Third Point Reinsurance (USA) Ltd., which both have ‘A-‘ (Excellent) financial strength ratings from AM Best.  With offices in Bermuda, New Jersey and London, the Third Point Re companies specialize in finding innovative solutions for niche and complex risks.  You can learn more by visiting: www.thirdpointre.com.

About Sirius Group
Sirius Group, with $2.5 billion of total capital and roots dating back to 1945, is a global multi-line (re)insurer headquartered in Bermuda with a unique global branch network, including offices in Stockholm, New York and London.  Sirius Group provides a fully diversified set of tailored risk products to clients in approximately 150 countries, including health and travel products to consumers through its two managing general underwriters, ArmadaCare and International Medical Group.  Sirius Group has been publicly traded on Nasdaq since November 2018.  You can learn more by visiting www.siriusgroup.com.

Where to Find Additional Information
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.  This communication may be deemed to be solicitation material in respect of the merger.  In connection with the merger, Third Point Re filed with the SEC on October 23, 2020 a final joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”), which was declared effective by the SEC, and each of Third Point Re and Sirius Group may be filing with the SEC other documents regarding the merger.  INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS, BECAUSE IT CONTAINS IMPORTANT INFORMATION.  Investors and security holders may obtain a free copy of the Joint Proxy Statement/Prospectus and other documents filed by Third Point Re and Sirius Group with the SEC at http://www.sec.gov.  Free copies of the Joint Proxy Statement/Prospectus and each company’s other filings with the SEC may also be obtained from the respective companies.  Free copies of documents filed with the SEC by Third Point Re will be made available free of charge on Third Point Re’s investor relations website at https://www.thirdpointre.com/investors/.  Free copies of documents filed with the SEC by Sirius Group will be made available free of charge on Sirius Group’s investor relations website at https://ir.siriusgroup.com/.

Forward-Looking Statements
Information set forth in this communication, including financial estimates and statements as to the expected timing, completion and effects of the proposed merger between Third Point Re and Sirius Group, constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These estimates and statements are subject to risks and uncertainties, and actual results might differ materially.  Such estimates and statements include, but are not limited to, statements about the date the transactions may be consummated, the benefits of the merger, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions, and other statements that are not historical facts.  Such statements are based upon the current beliefs and expectations of the management of Third Point Re and Sirius Group and are subject to significant risks and uncertainties outside of our control.  Among the risks and uncertainties that could cause actual results to differ from those described in the forward-looking statements are the following: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, (2) the risk that the necessary regulatory approvals may not be obtained or may be obtained subject to conditions that are not anticipated, (3) risks that any of the closing conditions to the proposed merger may not be satisfied in a timely manner, and (4) the risk that SiriusPoint may not achieve the expected benefits of the transaction.  Discussions of additional risks and uncertainties are contained in Third Point Re’s and Sirius Group’s filings with the Securities and Exchange Commission.  Neither Third Point Re nor Sirius Group is under any obligation, and each expressly disclaims any obligation, to update, alter, or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise.  Persons reading this announcement are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof.

Contact Us

For Third Point Re

Media

Mairi Mallon

Rein4ce
[email protected]
+44 7843 067533

Investor

Christopher S. Coleman – Chief Financial Officer
+1 (441) 542-3333
[email protected]  

For Sirius Group

Lynda Caravello

+1 (215) 603-7697
[email protected]

View original content:http://www.prnewswire.com/news-releases/third-point-reinsurance-ltd-and-sirius-international-insurance-group-ltd-announce-election-deadline-for-sirius-group-shareholders-301223342.html

SOURCE Third Point Reinsurance Ltd.

NEW YORK, Feb. 5, 2021 /PRNewswire/ — Oscar Health, Inc. (“Oscar”) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its Class A common stock. Oscar intends to list its Class A common stock on the New York Stock Exchange under the ticker symbol “OSCR.” The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, Morgan Stanley and Allen & Company LLC are acting as lead managing bookrunners for the proposed offering with Wells Fargo Securities as managing bookrunner. BofA Securities and Credit Suisse are also acting as bookrunners. Cowen and LionTree are acting as co-managers, with Ramirez & Co., Inc. and Siebert Williams Shank as junior co-managers for the proposed offering.

The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the proposed offering, when available, may be obtained from any of the following sources:

• Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected];
• Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014;
• Allen & Company LLC, Attention: Prospectus Department, 711 Fifth Avenue, New York, NY 10022;
• Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897, or via email: [email protected];
• BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255, or via email: [email protected]; or
• Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560.

A registration statement on Form S-1 relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Oscar Health, Inc.
Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all.

Headquartered in New York City, Oscar has been challenging the health care system’s status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of approximately 529,000 Americans across 291 counties, as of January 31, 2021. We offer Individual & Family, Small Group and Medicare Advantage plans.

Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.

View original content to download multimedia:http://www.prnewswire.com/news-releases/oscar-health-inc-announces-filing-of-registration-statement-for-proposed-initial-public-offering-301223341.html

SOURCE Oscar Health, Inc.

TORONTO, Feb. 5, 2021 /CNW/ – Alexandra Woodyer Sherron, President and Chief Executive Officer, Empress Royalty Corp. (“Empress” or the “Company”) (TSXV: EMPR), and her team joined Arne Gulstene, Head, Company Services, TMX Group, to celebrate the company’s new listing on TSX Venture Exchange and close the market.

Empress Royalty Corp. is a new royalty and streaming creation company with a portfolio consisting of exclusively precious metals investments. Empress is focused on investing in development and production stage projects providing unique financing solutions for mining companies who require additional non dilutive capital. The Company has strategic relationships with Endeavour Financial, Terra Capital and Accendo Banco. These relationships allow Empress to not only access global investment opportunities but also bring unique mining finance expertise, deal structuring and access to capital markets. Empress is looking forward to creating value for its shareholders through quality cash producing royalty and streaming investments. For more information visit: https://www.empressroyalty.com/ 

SOURCE TMX Group Limited

SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the commencement of a proposed registered underwritten public offering by certain pre-IPO shareholders (the “Selling Shareholders”) of American depositary shares (the “ADSs”), each ten (10) ADSs representing twenty-three (23) ordinary shares of the Company. The Selling Shareholders propose to offer an aggregate of 3,283,950 ADSs (the “ADS Offering”). The Selling Shareholders will also grant the underwriters a 30-day option to purchase up to 492,590 additional ADSs.

The Company will not receive any proceeds from the sale of the ADSs by the Selling Shareholders.

BofA Securities, Inc., Piper Sandler & Co. and Cantor Fitzgerald & Co. act as joint bookrunners for the ADS Offering.

The ADS Offering is being made only by means of a prospectus supplement and the accompanying prospectus included in an automatic shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 5, 2021, which automatically became effective upon filing. The registration statement on Form F-3 and the preliminary prospectus supplement dated February 5, 2021 are available on the SEC website at: http://www.sec.gov. The final prospectus supplement will be filed with the SEC and will be available on the SEC’s website at: http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, or by emailing [email protected]; Piper Sandler & Co., Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or by email: [email protected]; and Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 499 Park Avenue, 6th Floor, New York, New York, 10022 or by email at [email protected].

This announcement shall not constitute an offer to sell, or a solicitation of an offer to buy, the securities described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company’s mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab’s globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company’s unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about I-Mab’s beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in I-Mab’s filings with the SEC. All information provided in this press release is as of the date of this press release, and I-Mab does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

I-Mab

Jielun Zhu, CFO
E-mail: 

[email protected]


Office line: +86 21 6057 8000

Gigi Feng, Chief Communication Officer
E-mail: 

[email protected]


Office line: +86 21 6057 5785

Investor Inquiries:

The Piacente Group, Inc.

Emilie Wu

E-mail: 

[email protected]


Office line: +86 21 6039 8363

View original content to download multimedia:http://www.prnewswire.com/news-releases/proposed-registered-secondary-public-offering-of-american-depositary-shares-by-certain-pre-ipo-shareholders-of-i-mab-301223339.html

SOURCE I-Mab